M6P-Modified RhGAA for Lysosomal Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Pompe disease, such as alglucosidase alfa, have sub-optimal effects due to poor tissue targeting and stability issues, leading to inadequate delivery of recombinant human acid α-glucosidase (rhGAA) to lysosomes, necessitating high doses and resulting in costly and time-consuming treatments.
Innovation Solution
A method for producing recombinant human lysosomal proteins, including rhGAA, involves culturing host cells to secrete the protein, followed by anion exchange chromatography to capture and purify it, ensuring a high content of mannose-6-phosphate residues for improved binding to cation-independent mannose-6-phosphate receptors, enhancing tissue targeting and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional enzyme replacement therapy with rhGAA is used, then the treatment can be administered, but the tissue targeting is poor and stability is insufficient, leading to inadequate delivery to lysosomes
Solution Approach 1:
The patent modifies the glycosylation parameters of rhGAA by expressing it in CHO cells, which naturally perform N-linked glycosylation. This results in the attachment of high-mannose glycans containing mannose-6-phosphate (M6P) residues to the rhGAA protein. The M6P residues are crucial for binding to cation-independent M6P receptors (CIMPR) on the cell surface, thereby improving tissue targeting efficiency and delivery to lysosomes.
Solution Approach 2:
The patent uses high-mannose glycans with M6P residues as intermediaries to facilitate the binding between rhGAA and CIMPR. These glycans act as mediators that enable the replacement enzyme to be recognized and internalized by target cells, overcoming the poor tissue targeting issue of conventional rhGAA products.
2Reliability
If high doses of rhGAA are administered to compensate for poor tissue targeting, then adequate enzyme delivery may be achieved, but the treatment becomes costly and time-consuming
Solution Approach 1:
By changing the glycosylation parameters of rhGAA through expression in CHO cells, the patent increases the content of M6P-bearing glycans on the enzyme. This modification improves the enzyme's ability to bind to CIMPR and be efficiently taken up by cells, thereby achieving adequate enzyme delivery at lower doses and reducing the overall quantity of substance required for treatment.
3Ease of manufacture
If conventional manufacturing processes are used for rhGAA, then production is simpler, but the M6P content is low, resulting in poor tissue targeting
Solution Approach 1:
The patent utilizes the endogenous N-linked glycosylation system of CHO cells to automatically attach high-mannose glycans with M6P residues to rhGAA during protein expression. This self-service mechanism eliminates the need for complex post-translational modification steps or chemical phosphorylation processes, maintaining ease of manufacture while achieving high M6P content.
Solution Approach 2:
The patent changes the manufacturing parameter of host cell selection from conventional expression systems to CHO cells, which naturally perform the required glycosylation. This parameter change simplifies the overall manufacturing process by leveraging the cell's inherent biochemical capabilities rather than requiring additional complex processing steps to introduce M6P residues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly improves the delivery and activity of rhGAA to muscle cells, leading to more effective glycogen clearance and potentially better clinical outcomes for Pompe disease patients, while reducing the need for high doses and associated costs.
Implementation Method 1
loading the filtrate onto an anion exchange chromatography (AEX) column to capture the lysosomal protein
Data Source
AI summary
Methods for the production, capturing and purification of recombinant human lysosomal proteins are described. Such recombinant human lysosomal proteins can have high content of mannose-6-phosphate residues. Also described are pharmaceutical compositions comprising such recombinant human lysosomal proteins, as well as methods of treatment and uses of such recombinant human lysosomal proteins.